Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06628700
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-03
Brief Title:
Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 Assess frequency of hepatic steatosis among patients in patients with Ischemic stroke without previous risk factors
2 Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis
2 Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis
Detailed Description:
Fatty liver disease encompassing both alcoholic and non-alcoholic variants is a growing health concern worldwide with prevalence rates soaring in parallel with obesity and diabetes epidemics The estimated global incidence of NAFLD alone is 47 cases per 1000 people with a higher rate observed in males than females Among adults worldwide the estimated prevalence of NAFLD is 32 with a higher prevalence in males 40 compared to females 26 making it the most common liver disorder The hazards of fatty liver disease extend beyond the liver itself The condition is characterized by the accumulation of excess fat in liver cells which can progress to more severe liver diseases such as steatohepatitis fibrosis cirrhosis and hepatocellular carcinoma
Early assessment and diagnosis of liver steatosis are crucial for managing and mitigating the risks associated with FLD Non-invasive methods such as elastography combined with the Controlled Attenuation Parameter CAP score have emerged as effective tools for detecting and quantifying liver fat content These methods offer a less invasive alternative to liver biopsies providing reliable data to guide clinical decisions
NAFLD is characterized by a proinflammatory and proatherogenic state that causes vascular inflammation and neurodegeneration potentially leading to both clinical and subclinical cerebrovascular disease Increasing epidemiological evidence links NAFLD to a higher risk and greater severity of stroke independent of other vascular risk factorsAdditionally studies suggest NAFLD is involved in subclinical cerebrovascular diseases such as carotid atherosclerosis which is characterized by the build-up of plaques in the carotid arteries Patients with NAFLD exhibited greater carotid atherosclerosis
Early assessment and diagnosis of liver steatosis are crucial for managing and mitigating the risks associated with FLD Non-invasive methods such as elastography combined with the Controlled Attenuation Parameter CAP score have emerged as effective tools for detecting and quantifying liver fat content These methods offer a less invasive alternative to liver biopsies providing reliable data to guide clinical decisions
NAFLD is characterized by a proinflammatory and proatherogenic state that causes vascular inflammation and neurodegeneration potentially leading to both clinical and subclinical cerebrovascular disease Increasing epidemiological evidence links NAFLD to a higher risk and greater severity of stroke independent of other vascular risk factorsAdditionally studies suggest NAFLD is involved in subclinical cerebrovascular diseases such as carotid atherosclerosis which is characterized by the build-up of plaques in the carotid arteries Patients with NAFLD exhibited greater carotid atherosclerosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None